European Journal of Rheumatology
Literature Review

Infections in Patients with Systemic Lupus Erythematosus: The Contribution of Primary Immune Defects Versus Treatment-Induced Immunosuppression

1.

Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, USA

Eur J Rheumatol 2023; 10: 148-158
DOI: 10.5152/eurjrheum.2023.23068
Read: 870 Downloads: 554 Published: 09 October 2023

Patients with systemic lupus erythematosus experience high rates of infections. The use of immunosuppressive drugs to treat the disease, along with the fact that both the innate and adaptive branches of the immune system are compromised, account for the development of infections. In this communication, we briefly discuss the aberrant function of the immune system in patients with systemic lupus erythematosus and review the occurrence of infections that have been reported in clinical trials conducted to develop new therapeutics. Understanding the immune dysfunction in patients with systemic lupus erythematosus and the appearance of infections while trying to control the disease using immunosuppressive or immunomodulatory drugs should help limit infections and mitigate the associated morbidity and mortality.

Cite this article as: Kunzler ALF, Tsokos G. Infections in patients with systemic lupus erythematosus: The contribution of primary immune defects versus treatment-induced immunosuppression. Eur J Rheumatol. 2023;10(4):148-158.

Files
EISSN 2148-4279